Running title: Phycocyanin inhibits pancreatic cancer metastasis

Phycocyanin inhibits pancreatic cancer metastasis via suppressing epithelial- mesenchymal transition and targeting Akt/ β -catenin pathway

Rongrong Huang[#], Gaoyong Liao[#], Meifeng Gao, Yu Ou^{*}

School of Life Science and Technology, China Pharmaceutical University, Nanjing, China

^{*}Correspondence: ouyu2008@126.com

[#]Contributed equally to this work.

Received June 9, 2021 / Accepted July 13, 2021

According to our previous research, phycocyanin (PC) could inhibit pancreatic tumor growth obviously. However, little is known about the effects of phycocyanin on pancreatic tumor metastasis. This study was aimed to investigate whether phycocyanin inhibits pancreatic cancer cells' metastasis and the potential underlying mechanisms. Human pancreatic carcinoma cell lines PANC-1 and BxPC3 were treated with phycocyanin (5, 10, 20, and 40 μ M) for 48 h or 72 h. BALB/c nude mice were inoculated intravenously with luciferase-PANC-1 cells to establish a tumor metastasis model. BALB/c nude mice were also inoculated subcutaneously with PANC-1 cells to establish a xenograft tumor model. Our results indicated that (1) phycocyanin inhibited migration, invasion, and movement of pancreatic cancer cells in vitro, and tumor metastasis in mouse xenograft tumor model; (2) phycocyanin significantly changed cell morphology and epithelial-mesenchymal transition (EMT) phenotype in pancreatic cancer cells; (3) phycocyanin decreased the phosphorylation level of Akt and the level of nuclear β -catenin. Moreover, administration of Akt activator SC79 counteracted the inhibitory effect of phycocyanin on the migration of pancreatic cancer cells, associated with the reversal of epithelial-mesenchymal transition and Akt/ β -catenin signaling pathway. Taken together, our results suggest that phycocyanin inhibits pancreatic cancer metastasis via suppressing epithelial-mesenchymal transition and targeting the Akt/ β -catenin pathway.

Key words: phycocyanin; pancreatic cancer cells; metastasis; epithelial-mesenchymal transition (EMT); Akt/ β -catenin

Pancreatic adenocarcinoma (PDAC) is a common malignant digestive system tumor in the world, which is highly aggressive. Although great strides are being made in medical science, the five-year survival rate for pancreatic cancer is still lower than 9% [1, 2]. Among various factors leading to cancer death, tumor metastasis has always been considered an important one [3]. Therefore,

45 treatment of pancreatic cancer also faces the challenge of tumor metastasis. Epithelial-mesenchymal
46 transition (EMT) is of vital importance to tumor metastasis in the early stage [4] and essential to the
47 epithelium-originated solid tumor metastasis cascade [5, 6]. In EMT process, the connection
48 between cells becomes loose, while the epithelial cells still remain intact, followed with decreasing
49 of cell polarity. Cells begin to show the characteristics of interstitial cells, eventually leading to
50 increased cell invasiveness [3, 7]. Meanwhile, cell morphological and migration behavior turn
51 similar to fibrosis along with epithelial marker E-cadherin downregulated and interstitial marker
52 upregulated. The decreased expression of E-cadherin is the most common indicator of the initiation
53 of EMT, and is related to the development of tumor metastasis [8]. Hence, EMT has represented a
54 novel and major target in anticancer therapy [9]. It is generally known that secondary tumor
55 metastasis is caused by tumor cell adhesion, migration, and proteolysis of extracellular matrix
56 (ECM). MMPs are vital factors to promote tumor metastasis by selectively regulating tumor
57 microenvironment, and it is also an inducer of EMT [10]. Among MMPs family, MMP9 can
58 degrade almost all the components of ECM, and regulate most signal pathways that promote EMT
59 [11, 12]. Cell adhesion molecules also play vital roles in EMT process. Intercellular adhesion
60 molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) were reported to be
61 upregulated as part of the mesenchymal phenotype during EMT, and participated in the dissociation
62 and migration of cancer cells [13, 14]. Thus, these factors can also be used as EMT markers in EMT
63 related researches.

64 Akt is a pivotal serine/threonine kinase in biological progress including cell proliferation, apoptosis,
65 and metabolism, and is known to promote EMT in tumor metastasis [15]. Available researches have
66 confirmed that Akt pathway plays an important role in EMT process and tumor metastasis of
67 pancreatic cancer. In addition, Akt participates in the modulation of EMT- specific proteins
68 including E- cadherin and vimentin [16, 17]. As all known, β -catenin stabilization is essential for
69 tumor invasion and metastasis in various cancer cells [18]. Evidence has shown that Akt can
70 directly or indirectly act on β -catenin, leading to its stabilization, increasing its transcriptional
71 activity, and promoting EMT [19].

72 The cyanobacterium *Spirulina platensis*, known as spirulina, contains a lot of bioactive compounds
73 [20]. Phycocyanin (PC), one of the major biliproteins present in spirulina, exerts multiple
74 physiological effects, and has a potential value in the area of functional and healthy food [21]. Our

previous study has indicated that phycocyanin can act as an anti-pancreatic cancer agent due to its ability to induce pancreatic cancer cells apoptosis and autophagy [22]. In this study, we approach to investigate whether and how phycocyanin inhibits the invasion and metastasis of pancreatic cancer cells. Our findings suggest that phycocyanin has an Akt/ β -catenin-dependent mechanism in EMT-mediated migration and invasion of pancreatic cancer cells.

Materials and methods

Reagents. Phycocyanin was isolated and purified from *Spirulina platensis* according to the protocols reported previously [23]. Isolated phycocyanin was prepared as a stock solution of 1 mM in PBS (pH 7.4) and stored at -80 °C. Before each experiment, the phycocyanin stock solution was diluted with RPMI-1640 medium (Gibco, USA). Nucleoprotein Extraction Kit was obtained from Beyotime Biotechnology (China). Primary antibody to E-cadherin (#3195), vimentin (#5741), fibronectin (#26836) and keratin (#13063) were available from Cell Signaling Technology (USA). Primary antibody against ICAM-1 (sc-8439), VCAM-1 (sc-13160), MMP-9 (sc-393859) and β -catenin (sc-7963) were purchased from Santa Cruz Biotechnology (USA). Primary antibody against α -tubulin (#AF5001) and GAPDH (#AF1186) were available from Beyotime Biotechnology (China). Secondary antibody HRP-conjugated Goat Anti-Rabbit IgG (#D110058) and HRP-conjugated Goat anti-mouse IgG (#D110087) were available from Sangon Biotech (China). D-luciferin (#2591-17-5) was from Sigma (Germany). SC79 (SML0749) was obtained from Sigma-Aldrich (USA).

Cell culture. Human pancreatic carcinoma cell lines PANC-1 and BxPC3 purchased from ATCC were cultured in RPMI-1640 at 37 °C in humidified air containing 5% CO₂. The culture medium was supplemented with 10% FBS, penicillin G (100 U/ml) and streptomycin (100 mg/ml).

Cell morphology assay. PANC-1 and BxPC3 cells were cultured in 12-well plates for 12 h in a density of 6×10^4 /well, then phycocyanin (5, 10, 20 and 40 μ M) were added to the medium. The cell morphology of each well was recorded with a microscope (Zeiss Series 120) 48 h later.

Microtubule morphology assay. PANC-1 and BxPC3 cells were seeded into 96-well plates, containing 1×10^4 cells each well. High concentration of phycocyanin group (40 μ M) were used to treat each kind of cells respectively for 48 h the next day, and then fixed with 4% paraformaldehyde in PBS for 1 h at room temperature. Afterwards, cells were permeabilized with 0.5% Triton X 100

105 for 10 min, blocked for 30 min with 2% BSA-PBS and incubated for 1 h with the
106 Rabbit-anti- α -tubulin antibody (dilution 1:200) in PBS at room temperature. They were then
107 incubated with the secondary antibody (dilution 1:500) for 1 h at room temperature. DAPI (dilution
108 1:2000) staining was then carried out during 5 min at room temperature after secondary antibody
109 incubation. The fluorescence of each cell was photographed on the High Content Screening
110 Instrument (Molecule Devices [ImageXpress]), and the image was fitted by merge with the software
111 of the instrument. The mean fluorescence intensity of α -tubulin was measured by ImageJ (Version
112 1.48).

113 **Wound healing assay.** To determine cell migration, PANC-1 and BxPC3 cells were seeded at $1 \times$
114 10^5 cells per well in 12-well plates. When cells were confluent, a pipette tip was used to scratch cell
115 monolayer across the diameter of each well. The new serum-free medium was added after removing
116 former medium and dislodged cells. The cells were incubated at 37 °C for 1 h, and then the medium
117 was replaced by the medium with phycocyanin (5, 10, 20 and 40 μ M) dissolved in 1%
118 FBS-Medium. Cells that migrated to the scratch area were photographed at 0 h and 72 h time points.
119 The cell-free area was measured by ImageJ (Version 1.48). The value of migration area was the
120 difference between the cell-free area at 0 h and the cell-free area at 72 h.

121 **Cell invasion assay.** Matrigel invasion assay was performed to examine the invasion ability of
122 PANC-1 and BxPC3 cells. Briefly, the upper surface of the membrane was coated with Matrigel.
123 Cancer cells were suspended in FBS-free medium, and then seeded in the upper chamber.
124 Phycocyanin was added to a final concentration of 5, 10 and 20 μ M. The bottom chamber of the
125 transwell plate was filled with culture medium containing 10% FBS, and the cells migrated to the
126 bottom surface of the transwell chambers through pores 48 h later. Then, they were fixed with
127 formaldehyde and stained with 0.1% Crystal Violet. Under the Olympus inverted microscope, each
128 group was counted with four randomly selected microscopic fields.

129 **Cell mobility assay.** PANC-1 cells were maintained in 96-well plates for 24 h, then labeled with
130 Qtracker565 Cell Labeling Kit (ThermoFisher) according to the instructions. Phycocyanin
131 maintained in RPMI-1640 medium supplemented with 1% FBS was then added into each well at
132 the series concentrations of 5, 10 and 20 μ M. Images were captured with a dynamic observation
133 every 30 min for 48 h, and the location of the cells was recorded by the High Content Screening
134 Instrument (Molecule Devices [ImageXpress]).

135 **Construction of Luciferase-PANC-1 stable cell line.** PANC-1 cells were seeded into 96-well
136 plates at a concentration of 1×10^5 cell/well, then different concentrations of puromycin were added
137 to corresponding holes to select an appropriate concentration. Luciferase plasmid virus packaging
138 was taken according to manufacturer's protocol (Guangzhou FuluGen Co., Ltd.). The supernatant
139 was collected to detect virus titer 48 h later strictly following the product instructions. Collected
140 virus was diluted into three concentration gradients. After 24 h infection, the cells were pressed by
141 Puromycin. After five days of pressure screening, the cell growth of the normal group and the
142 infection group was compared. When the difference was found, the monoclonal to the 96-well plate
143 was selected by the finite dilution method, and the use of puromycin was gradually reduced. Several
144 monoclonal were picked out to expand culture and freeze. The activated clones were frozen and
145 preserved for at least one week after the identification. The repetitive luciferase functional
146 identification of seven clones after the passage of the recovered cells was carried out. The luciferase
147 activity was identified strictly according to the luciferase activity detection kit (Promega)
148 instructions. D-luciferin was used to confirm that each clone was successfully labelled with
149 luciferase gene (Supplementary Figure S1).

150 **Tumor metastasis model and Luciferase imaging.** The animal procedures were performed in
151 accordance with the guidelines of the institutional animal care and use committee of China
152 Pharmaceutical University Licensing Committee (License No. SYXK (SU) 2018-0019). The
153 experiment was conducted according to approved guidelines. Six-week-old BALB/c nude mice
154 were inoculated intravenously with Luciferase-PANC-1 stable cell lines (1×10^6 cells in 200 μ l of
155 serum-free RPMI-1640 medium). Two days after inoculation, phycocyanin was injected
156 intraperitoneally every two days to mice of different group at the concentrations of 12.5 mg/kg, 25
157 mg/kg and 50 mg/kg respectively during a thirty-day experiment. At the end of the experiment,
158 mice were anesthetized by isoflurane, and then were injected intraperitoneally with D-luciferin
159 substrate (150 mg/kg in PBS) 10 min before imaging. Light emission from luciferase was detected
160 by using a living animal imaging system (NightOwl LB983, Berthold Technologies).

161 **Xenograft tumor experiment.** The animal procedures were performed in accordance with the
162 guidelines of the institutional animal care and use committee of China Pharmaceutical University
163 Licensing Committee (License No. SYXK (SU) 2018-0019). The experiment was conducted
164 according to approved guidelines. Six-week-old BALB/c nude mice were inoculated

165 subcutaneously with human pancreatic carcinoma PANC-1 cells (5×10^6 cells in 100 μ l of
166 serum-free RPMI-1640 medium) into the axillary fossa. The mice were randomly divided into four
167 groups with three mice for each group. They are 0.9% normal saline group (control), 10 mg/kg
168 phycocyanin group, 25 mg/kg phycocyanin group and 50 mg/kg phycocyanin group. During the
169 thirty-day experiment, phycocyanin and vehicle were injected intraperitoneally to mice every two
170 days. At the end of treatment, all mice were sacrificed and tumors were excised for further
171 immunohistochemistry assay and western blot assay.

172 **Immunohistochemistry assay.** The tissue was embedded by paraffin and then cut into 3- μ m thick
173 continuous sections by using a microtome (Finesse ME, Thermo Scientific). The slides went
174 through the following steps including drying and dewaxing by xylene, rehydration by graded
175 ethanol, blocking endogenous peroxidase activity by immersion in 3% hydrogen peroxide for 10
176 min and antigen recovery by autoclaving for 3 min in citrate buffer (pH=6). In order to avoid
177 nonspecific reaction, the slides were incubated with 5% BSA for 15 min before incubation with the
178 indicated primary antibody (dilution 1:200) for 50 min at 37 °C and subsequently incubation with a
179 secondary antibody (dilution 1:1000) for 30 min at 37 °C. Then they were stained with DAB
180 (3,3-diaminobenzidine) and counterstained with Mayer's hematoxylin. The last steps were
181 dehydration and mounting. In the negative control, a normal rabbit IgG replaced the primary
182 antibody.

183 **Western blot assay.** Tumor tissues and cells were washed with ice-cold PBS. Their lysates were
184 obtained by incubation for 20 min in buffer of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
185 EDTA, 1 mg/ml pepstatin A, 1 mM PMSF and 1% Triton X-100. The homogenate was centrifuged
186 for 20 min with $10,000 \times g$, and then the supernatant was collected and quantified by BCA
187 (Bicinchoninic acid). The nucleoproteins were obtained with a Nucleoprotein Extraction Kit. The
188 lysates were loaded to 10-14% SDS-PAGE and transferred to PVDF membranes. Then the
189 membranes underwent sequentially the blocking, the incubation with the primary antibodies
190 (dilution 1:1000) at 4 °C for 12 h and the incubation with secondary antibodies (dilution 1:5000)
191 conjugated with corresponding horseradish peroxidase for 1 h. After each incubation step,
192 membranes were washed in Tris-buffered saline containing 0.5% Tween-20 for 3 times, each time
193 for 5 min. ECL was used to visualize the corresponding bands with Tanon-5200 Chemiluminescent
194 Imaging System (Tanon Science & Technology Co.,Ltd).

195 **Statistical analysis.** Data were expressed as the mean $\pm$ SD. The statistical significance of the
196 differences between the experimental variables and their reference group was determined using the
197 Student's *t*-test; $p < 0.05$ was considered statistically significant.

198

199 **Results**

200 **Phycocyanin inhibits migration, invasion and movement of pancreatic cancer cells *in vitro*.**

201 Cell migration experiment showed that phycocyanin (5, 10, 20 and 40 μ M) inhibited PANC-1 and
202 BxPC3 cells migration in a dose dependent manner (Figures 1A, 1B). Phycocyanin also inhibited
203 cell invasion ability significantly (Figure 1C). The number of invasion cells gradually decreased
204 from 200 to about 10 by treating with phycocyanin (Figure 1D). Referring to the effects of
205 phycocyanin on PANC-1 cell movement, the result of real-time scanning imaging assay suggested
206 that the trajectory (Figure 1E position) and the movement range (Figure 1E distance) of almost all
207 normal cells were longer, while the number of long trajectory cells decreased dose-dependently
208 with the treatment of phycocyanin. The results fully demonstrated that phycocyanin inhibited the
209 movement of pancreatic cancer cells.

210 **Phycocyanin changed cell morphology and EMT markers in pancreatic cancer cells.** During
211 EMT, the distribution and expression of cytoskeleton altered, usually accompanied by the change of
212 cell morphology [15]. As shown in Figure 2A, under the treatment of phycocyanin (5, 10, 20 and 40
213 μ M), PANC-1 and BxPC3 cells showed obvious morphological alteration. Immunofluorescence
214 assay further confirmed that phycocyanin altered the morphology and distribution of microtubules
215 significantly (Figures 2B, 2C). Furthermore, phycocyanin also increased the expression of epithelial
216 cell marker molecules E-Cadherin and keratin-8 in pancreatic cancer cell lines time-dependently,
217 while reduced the expression of interstitial cell marker molecules N-cadherin, fibronectin and
218 vimentin (Figure 2D).

219 **Phycocyanin inhibited the metastasis of pancreatic cancer cells *in vivo*.** To investigate the
220 inhibitory effect of phycocyanin on the tumor metastasis, PANC-1-Luciferase cells were used to
221 track the movement of tumor cells in nude mice. As shown in Figure 3A, PANC-1-Luciferase cells
222 in control group transferred throughout the body along with intense luminescence, while under the
223 treatment of phycocyanin, tumor metastasis was obviously suppressed dose-dependently, especially
224 in the high dose group. In order to verify the inhibition of phycocyanin on EMT, we firstly detected

225 ICAM-1, VCAM-1 and MMP-9 expression in xenograft tumor in the nude mice. As shown in
226 Figure 3B, phycocyanin could reduce the expression of ICAM-1, VCAM-1 and MMP-9 in tumor
227 tissues. For further confirmation, we used immunohistochemistry assay to detect the expression
228 level of epithelial marker E-cadherin and interstitial markers vimentin and fibronectin in tumor
229 tissues. As shown in Figures 3C and 3D, phycocyanin could significantly increase the expression
230 level of E-cadherin and decrease expression levels of vimentin and fibronectin. Combined the
231 results of the expression of EMT markers *in vitro* and *in vivo*, phycocyanin significantly changed
232 EMT phenotype in pancreatic cancer cells.

233 **Phycocyanin inhibited the Akt/ β -catenin pathway in pancreatic cancer cells.** To determine the
234 downstream mechanisms underlying the role of phycocyanin in the metastasis of pancreatic cancer
235 cells, phycocyanin was examined in terms of inhibiting Akt activity. As expected, introduction of 20
236 μ M phycocyanin into PANC-1 and BxPC3 cells significantly suppressed Akt phosphorylation
237 (Figure 4A). These results indicated that phycocyanin normally acted to suppress Akt activity in
238 pancreatic cancer cells. The transcription factor β -catenin, as a direct or indirect downstream target
239 of Akt, is widely known to crucially affect tumor invasion and metastasis [19]. Hence, the
240 expression of nuclear β -catenin was detected by using western blot assay. As our results shown,
241 phycocyanin reduced nuclear β -catenin level of PANC-1 and BxPC3 cells significantly (Figure 4B).

242 **Akt activator counteracted the inhibitory effect of phycocyanin on the migration of pancreatic**
243 **cancer cells.** To further confirm the relationship between Akt overactivation and the inhibitory
244 effect of phycocyanin on the migration, PANC-1 cells were treated with Akt activator SC79. From
245 the result, SC79 could effectively counteract the inhibitory effect of phycocyanin on Akt
246 phosphorylation in pancreatic cancer cells (Figure 5A). Besides, SC79 also reversed the inhibitory
247 effect of phycocyanin on the migration of PANC-1 and BxPC3 cells (Figures 5B, 5C). Therefore,
248 these results suggested that phycocyanin inhibited the migration of pancreatic cancer cells via pAkt
249 downregulation.

250 **Akt/ β -catenin pathway was vital for phycocyanin to suppress pancreatic cancer cell EMT.** Akt
251 activation is known to promote EMT [15]. As shown in Figure 6A, under the action of Akt activator
252 SC79, the phycocyanin-induced expression of EMT biomarkers (E-cadherin, keratin-8, N-cadherin,
253 fibronectin and vimentin) in pancreatic cancer cells was reversed. This result indicated that
254 phycocyanin reversed EMT process through Akt inactivation in pancreatic cancer cells. On the

other hand, immunofluorescence assay showed that without SC79, phycocyanin inhibited the nuclear translocation of transcription factor β -catenin, while with SC79, the inhibitory effect was reversed (Figure 6B). Based on these results, Akt/ β -catenin axis was thought to potentially mediate the effect of phycocyanin on EMT process of pancreatic cancer cells.

Discussion

Increasing evidence showed that phycocyanin has the anti-cancer effect [24]. Our previous study has demonstrated that phycocyanin can inhibit the growth of various cancer cell lines as well as pancreatic cancer effectively in mouse xenograft tumor model [24]. In this study, we used classical cell scratch method and Matrigel matrix gel invasion method to determine the effect of phycocyanin on the metastasis function of pancreatic cancer cells. Additionally, we used real-time live cell imaging to intuitively describe the cell movement of pancreatic cancer cells. Our findings presented that phycocyanin inhibited migration, invasion and movement of pancreatic cancer cells *in vitro*, and the tumor metastasis in mouse xenograft tumor model.

The EMT phenotype is associated with pancreatic cancer cell metastasis [25-27]. In fact, there are many natural plant ingredients that can inhibit epithelial mesenchymal transition and show effective anti-cancer effect, mainly including flavonoids, polyphenols and alkaloids [28]. We demonstrated that phycocyanin treatment could suppress EMT phenotype acquisition by down-regulating the mesenchymal cell marker and up-regulating of the epithelial cell marker. The EMT process is a gradual process in highly metastatic tumor and plays a cumulative role in the adhesion of tumor cells at a specific level [3]. Adhesion molecules ICAM-1 and VCAM-1 in tumor tissues play important roles in tumor progression and metastasis [13, 29]. Consequently, it is of great significance to detect the expression of adhesion molecules as a way to measure tumor metastasis [30]. Moreover, matrix metalloproteinases (MMPs) are essential to promote tumor metastasis via selectively regulating the tumor microenvironment to promote tumor cell metastasis, as well as to induce EMT [10]. Activated MMPs degrade ECM components, causing cancer cells expansion without resistance, and there is a positive correlativity between MMP-9 and pancreatic cancer cell invasion [31]. Indeed, our results showed that phycocyanin could significantly reduce the expression of ICAM-1, VCAM-1 and MMP-9 in tumor tissues. These indicated that phycocyanin contributed to inhibiting pancreatic cells metastasis, partly by regulating adhesion molecules and

285 MMP expression and controlling ECM degradation.
286 In addition, EMT involves reorganization of the cytoskeleton. During EMT, cell morphology may
287 undergo external changes as a result of changes in the distribution and expression of cytoskeleton
288 [32]. Microtubules are the main components of cytoskeleton, which consist of α and β -tubulin
289 dimers. Through their dynamic characteristics, they have been proved to control the intracellular
290 transport, molecular signaling and directional movement of cells [15]. We used
291 immunofluorescence method to qualitatively analyze the microtubule (α -tubulin) induced by
292 phycocyanin in pancreatic cancer cells, and the results showed that the distribution of microtubules
293 in pancreatic cancer cells was altered by phycocyanin.

294 Akt activation could promote EMT [15], and impact on cancer cells growth, polarity, migration and
295 invasion [18]. It has been reported that EMT regulation need the involvement of β -catenin in
296 multiple human cancers [33]. Enhancement of β -catenin stability and transcriptional activity caused
297 by Wnt-dependent or independent signal transduction plays a key role in tumor invasion and
298 metastasis [18]. Activated Akt can stabilize β -catenin by phosphorylation and/or inhibiting GSK-3 β ,
299 thereby removing it from cell-to-cell contacts and nuclear accumulation [19]. In the present study,
300 we found that phycocyanin blocked the activation of Akt and the nuclear localization of β -catenin in
301 pancreatic cancer cells. To validate the role of Akt/ β -catenin pathway, we used the Akt activator
302 SC79 to maintain Akt activation in pancreatic cancer cells. The results showed that the effect of
303 phycocyanin on pancreatic cancer cell migration and EMT phenotype was completely suppressed
304 by Akt activator SC79. In addition, the decreased level of nuclear β -catenin in the pancreatic cancer
305 cells when treated with phycocyanin was also increased when SC79 used. It is possible to indicate
306 that Akt/ β -catenin pathway is involved in the role of phycocyanin against pancreatic cancer
307 metastasis.

308 Taken together, our results reveal the function and mechanisms of phycocyanin in regulating
309 pancreatic tumor metastasis. We demonstrated that phycocyanin inhibited pancreatic cancer cells
310 metastasis via suppressing epithelial- mesenchymal transition and targeting Akt/ β -catenin pathway.

311
312 Acknowledgements: This work was funded by the Priority Academic Program Development of
313 Jiangsu Higher Education Institutions (PAPD).

314

315 **Supplementary data are available in the online version of the paper.**

316

317

318 **References**

319

- 320 [1] RYAN DP, HONG TS, BARDEESY N. Pancreatic adenocarcinoma. *N Engl J Med* 2014;
321 371: 1039-1049. <http://doi.org/10.1056/NEJMra1404198>
- 322 [2] QUARESMA M, COLEMAN MP, RACHET B. 40-year trends in an index of survival for
323 all cancers combined and survival adjusted for age and sex for each cancer in England and
324 Wales, 1971-2011: a population-based study. *Lancet* 2015; 385: 1206-1218.
325 [http://doi.org/10.1016/S0140-6736\(14\)61396-9](http://doi.org/10.1016/S0140-6736(14)61396-9)
- 326 [3] KOTIYAL S, BHATTACHARYA S. Events of Molecular Changes in
327 Epithelial-Mesenchymal Transition. *Crit Rev Eukaryot Gene Expr* 2016; 26: 163-171.
328 <http://doi.org/10.1615/CritRevEukaryotGeneExpr.2016016307>
- 329 [4] RHIM AD, MIREK ET, AIELLO NM, MAITRA A, BAILEY JM et al. EMT and
330 dissemination precede pancreatic tumor formation. *Cell* 2012; 148: 349-361.
331 <http://doi.org/10.1016/j.cell.2011.11.025>
- 332 [5] HU J, LI L, CHEN H, ZHANG G, LIU H et al. MiR-361-3p regulates ERK1/2-induced
333 EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. *Cell Death Dis*
334 2018; 9: 807. <http://doi.org/10.1038/s41419-018-0839-8>
- 335 [6] MIYATAKE Y, OHTA Y, IKESHITA S, KASAHARA M. Anchorage-dependent
336 multicellular aggregate formation induces a quiescent stem-like intractable phenotype in
337 pancreatic cancer cells. *Oncotarget* 2018; 9: 29845-29856.
338 <http://doi.org/10.18632/oncotarget.25732>
- 339 [7] HU Y, YU X, XU G, LIU S. Metastasis: an early event in cancer progression. *J Cancer Res*
340 *Clin Oncol* 2017; 143: 745-757. <http://doi.org/10.1007/s00432-016-2279-0>
- 341 [8] MATOS ML, LAPYCKYJL, ROSSO M, BESSO MJ, MENCUCCI MV et al. Identification
342 of a Novel Human E-Cadherin Splice Variant and Assessment of Its Effects Upon
343 EMT-Related Events. *J Cell Physiol* 2017; 232: 1368-1386. <http://doi.org/10.1002/jcp.25622>
- 344 [9] SALEHI B, VARONI EM, SHARIFI-RAD M, RAJABI S, ZUCCA P et al.
345 Epithelial-mesenchymal transition as a target for botanicals in cancer metastasis.
346 *Phytomedicine* 2019; 55: 125-136. <http://doi.org/10.1016/j.phymed.2018.07.001>
- 347 [10] CHEN Y, HUANG L, WANG S, LI JL, LI M et al. WFDC2 contributes to
348 epithelial-mesenchymal transition (EMT) by activating AKT signaling pathway and
349 regulating MMP-2 expression. *Cancer Manag Res* 2019; 11: 2415-2424.
350 <http://doi.org/10.2147/CMAR.S192950>
- 351 [11] SUN SJ, WANG N, SUN ZW, CHEN J, CUI HW. MiR-5692a promotes the invasion and
352 metastasis of hepatocellular carcinoma via MMP9. *Eur Rev Med Pharmacol Sci* 2018; 22:
353 4869-4878. http://doi.org/10.26355/eurrev_201808_15623
- 354 [12] XU W, YANG Z, LU N. A new role for the PI3K/Akt signaling pathway in the
355 epithelial-mesenchymal transition. *Cell Adh Migr* 2015; 9: 317-324.
356 <http://doi.org/10.1080/19336918.2015.1016686>

- 357 [13] BAI J, ADRIANI G, DANG TM, TU TY, PENNY HX et al. Contact-dependent carcinoma
358 aggregate dispersion by M2a macrophages via ICAM-1 and beta2 integrin interactions.
359 *Oncotarget* 2015; 6: 25295-25307. <http://doi.org/10.18632/oncotarget.4716>
- 360 [14] SAMATOV TR, TONEVITSKY AG, SCHUMACHER U. Epithelial-mesenchymal
361 transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and
362 modulating compounds. *Mol Cancer* 2013; 12: 107.
363 <http://doi.org/10.1186/1476-4598-12-107>
- 364 [15] PONGRAKHANANON V, WATTANATHAMSAN O, TAKEICHI M, CHETPRAYOON
365 P, CHANVORACHOTE P. Loss of CAMSAP3 promotes EMT via the modification of
366 microtubule-Akt machinery. *J Cell Sci* 2018; 131: jcs216168.
367 <http://doi.org/10.1242/jcs.216168>
- 368 [16] LIAO G, WANG M, OU Y, ZHAO Y. IGF-1-induced epithelial-mesenchymal transition in
369 MCF-7 cells is mediated by MUC1. *Cell Signal* 2014; 26: 2131-2137.
370 <http://doi.org/10.1016/j.cellsig.2014.06.004>
- 371 [17] LI W, JIANG Z, XIAO X, WANG Z, WU Z et al. Curcumin inhibits superoxide
372 dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-kappaB
373 pathway in pancreatic cancer cells. *Int J Oncol* 2018; 52: 1593-1602.
374 <http://doi.org/10.3892/ijo.2018.4295>
- 375 [18] WANG C, RUAN P, ZHAO Y, LI X, WANG J et al. Spermidine/spermine
376 N1-acetyltransferase regulates cell growth and metastasis via AKT/beta-catenin signaling
377 pathways in hepatocellular and colorectal carcinoma cells. *Oncotarget* 2017; 8: 1092-1109.
378 <http://doi.org/10.18632/oncotarget.13582>
- 379 [19] FANG D, HAWKE D, ZHENG Y, XIA Y, MEISENHEDER J et al. Phosphorylation of
380 beta-catenin by AKT promotes beta-catenin transcriptional activity. *J Biol Chem* 2007; 282:
381 11221-11229. <http://doi.org/10.1074/jbc.M611871200>
- 382 [20] CARRIZZO A, CONTE GM, SOMMELLA E, DAMATO A, AMBROSIO M et al. Novel
383 Potent Decameric Peptide of *Spirulina platensis* Reduces Blood Pressure Levels Through a
384 PI3K/AKT/eNOS-Dependent Mechanism. *Hypertension* 2019; 73: 449-457.
385 <http://doi.org/10.1161/HYPERTENSIONAHA.118.11801>
- 386 [21] HAO S, LI S, WANG J, ZHAO L, YAN Y et al. C-Phycocyanin Suppresses the In Vitro
387 Proliferation and Migration of Non-Small-Cell Lung Cancer Cells through Reduction of
388 RIPK1/NF-kappaB Activity. *Mar Drugs* 2019; 17: 362. <http://doi.org/10.3390/md17060362>
- 389 [22] LIAO G, GAO B, GAO Y, YANG X, CHENG X et al. Phycocyanin Inhibits Tumorigenic
390 Potential of Pancreatic Cancer Cells: Role of Apoptosis and Autophagy. *Sci Rep* 2016; 6:
391 34564. <http://doi.org/10.1038/srep34564>
- 392 [23] SEO Y C, CHOI W S, PARK JH, PARK JO, JUNG KH et al. Stable isolation of
393 phycocyanin from *Spirulina platensis* associated with high-pressure extraction process. *Int J*
394 *Mol Sci* 2013; 14: 1778-1787. <http://doi.org/10.3390/ijms14011778>
- 395 [24] JIANG L, WANG Y, YIN Q, LIU G, LIU H et al. Phycocyanin: A Potential Drug for
396 Cancer Treatment. *J Cancer* 2017; 8: 3416-3429. <http://doi.org/10.7150/jca.21058>
- 397 [25] CHEN J, LI Q, AN Y, LV N, XUE X et al. CEACAM6 induces epithelial-mesenchymal
398 transition and mediates invasion and metastasis in pancreatic cancer. *Int J Oncol* 2013; 43:
399 877-885. <http://doi.org/10.3892/ijo.2013.2015>
- 400 [26] YEUNG KT, YANG J. Epithelial-mesenchymal transition in tumor metastasis. *Mol Oncol*
401 2017; 11: 28-39. <http://doi.org/10.1002/1878-0261.12017>

- [27] SINGH M, YELLE N, VENUGOPAL C, SINGH SK. EMT: Mechanisms and therapeutic implications. *Pharmacol Ther* 2018; 182: 80-94. <http://doi.org/10.1016/j.pharmthera.2017.08.009>
- [28] ZHANG L, WANG X, LAI M. Modulation of epithelial-to-mesenchymal cancerous transition by natural products. *Fitoterapia* 2015; 106: 247-255. <http://doi.org/10.1016/j.fitote.2015.09.013>
- [29] ROSETTE C, ROTH RB, OETH P, BRAUN A, KAMMERER S et al. Role of ICAM1 in invasion of human breast cancer cells. *Carcinogenesis* 2005; 26: 943-950. <http://doi.org/10.1093/carcin/bgi070>
- [30] VON BURSTIN J, BACHHUBER F, PAUL M, SCHMID RM, RUSTGI AK. The TALE homeodomain transcription factor MEIS1 activates the pro-metastatic melanoma cell adhesion molecule Mcam to promote migration of pancreatic cancer cells. *Mol Carcinog* 2017; 56: 936-944. <http://doi.org/10.1002/mc.22547>
- [31] GRUNWALD B, VANDOOREN J, GERG M, AHOMAA K, HUNGER A et al. Systemic Ablation of MMP-9 Triggers Invasive Growth and Metastasis of Pancreatic Cancer via Deregulation of IL6 Expression in the Bone Marrow. *Mol Cancer Res* 2016; 14: 1147-1158. <http://doi.org/10.1158/1541-7786.MCR-16-0180>
- [32] YILMAZ M, CHRISTOFORI G. EMT, the cytoskeleton, and cancer cell invasion. *Cancer Metastasis Rev* 2009; 28: 15-33. <http://doi.org/10.1007/s10555-008-9169-0>
- [33] WANG X, WANG S, LI X, JIN S, XIONG F et al. The critical role of EGF-beta-catenin signaling in the epithelial-mesenchymal transition in human glioblastoma. *Onco Targets Ther* 2017; 10: 2781-2789. <http://doi.org/10.2147/OTT.S138908>

Figure Legends

Figure 1. Phycocyanin inhibited migration, invasion and movement of pancreatic cancer cells *in vitro*. A) Wound healing assay was performed to assess the effect of phycocyanin on the migration of PANC-1 and BxPC3 human pancreatic cancer cells. The cells were treated with different doses of phycocyanin for 72 h. The 0 h panel indicates the original space between the cell layers immediate after making a scratch ($\times 200$ magnification). Scale bar=100 μm . B) Quantitation of the cells wound healing assay. Data were presented as mean $\pm$ SD, *** $p < 0.001$ vs. Control, $n=3$. C) Matrigel invasion assay was performed to examine the effect of phycocyanin on the invasive capacity of PANC-1 and BxPC3 cells. The cells were seeded in Matrigel-coated Boyden chambers and were incubated with different doses of phycocyanin as indicated. After 48 h, the cells invading the membranes were stained and then counted ($\times 200$ magnification). Scale bar=100 μm . D) Quantitation of the cell invasion. Data were presented as mean $\pm$ SD, ** $p < 0.01$ vs. Control, $n=4$. E) Effect of phycocyanin on the pancreatic cancer cell motion. The movement tracks of PANC-1 cells along the time-lapse sequences from the first frame to the 96 th frames, covering 48 h *in vitro*. The

440 tracks have been automatically corrected and verified (position). Mean deviation of cell positions
441 was obtained by the registration software from those obtained using Retrac against the all the 96
442 frames (distance).

443

444 **Figure 2.** Effects of phycocyanin on the morphology, microtubule morphology and the transition
445 from mesenchymal-to-epithelial in pancreatic cancer cells. A) Phycocyanin induced the
446 morphological changes of PANC-1 and BxPC3 cells. Cells were treated with indicated
447 concentration of phycocyanin and images were taken at the indicated time points ($\times 400$
448 magnification). Scale bar=50 μm . B) Phycocyanin-induced change of cytoskeletal structure of
449 pancreatic cells. PANC-1 and BxPC3 cells were incubated without (Control) or with 40 μM
450 phycocyanin in serum-containing medium for 48 h. These cells were fluorescence-stained for
451 α -tubulin (green) by using a specific antibody and DAPI (blue). Fluorescence images were obtained
452 with a High Content Screening System ($\times 400$ magnification). Scale bar=50 μm . C) Quantitation of
453 the α -tubulin (green) fluorescence intensity. Data were presented as mean $\pm$ SD, *** $p < 0.001$ vs.
454 Control, $n=3$. D) The levels of epithelial and mesenchymal biomarkers in PANC-1 and BxPC3 cells
455 after treatment with phycocyanin were verified using western blot analysis.

456

457 **Figure 3.** Phycocyanin inhibited the metastasis of pancreatic cancer cells in nude mice. A) Whole
458 animal imaging analysis of mice ($n=3/\text{group}$). PANC-1-Luciferase cells (1×10^6) were injected
459 intravenously into nude mice ($n=3$). Mice were treated with intraperitoneal injection of indicated
460 phycocyanin (every other day). Images of mice from control and treatment groups are shown on day
461 30 after cell implantation. B) Western blot analysis for the expression of ICAM-1, VCAM-1 and
462 MMP-9 in tumor tissue ($n=3/\text{group}$). C) Representative images of immunohistochemistry staining
463 of E-cadherin, vimentin and fibronectin in the PANC-1 xenografts ($\times 400$ magnification). Scale
464 bar=50 μm . D) Quantitation of the immunohistochemistry staining. Data were presented as
465 mean $\pm$ SD, *** $p < 0.001$ vs. Control, $n=3$.

466

467 **Figure 4.** Phycocyanin inhibited the phosphorylation of Akt and β -catenin nuclear translocation in
468 pancreatic cancer cells. A) Western blot analysis of pAkt and total Akt in PANC-1 and BxPC3 cells.
469 GAPDH was shown as a loading control, $n=3$. B) Western blot analysis of β -catenin in the nucleus.

470 Histone H3 was shown as a loading control, n=3.

471

472 **Figure 5.** Akt activator SC79 counteracts phycocyanin-induced migration inhibition in pancreatic
473 cancer cell line PANC-1. A) p-Akt and Akt were analyzed by immunoblotting. B) Cell migration
474 was examined by wound healing assay. Cells were preincubated with 500 ng/ml SC79 for 1 h and
475 then treated with or without 20 μ M phycocyanin for 48 h ($\times 200$ magnification). Scale bar=100 μ m.
476 C) Quantitation of the cells wound healing assay. Data were presented as mean $\pm$ SD, ***p < 0.001
477 vs. Control, n=3.

478

479 **Figure 6.** Phycocyanin inhibits EMT of pancreatic cancer cells through Akt/ β -catenin axis. A) SC79
480 reversed the effect of phycocyanin on EMT. The expression levels of E-cadherin, keratin-8,
481 N-cadherin, fibronectin, and vimentin in PANC-1 and BxPC3 cells were measured by western
482 blotting, n=3. B) The translocation of β -catenin was demonstrated by immunofluorescence staining
483 ($\times 400$ magnification). Scale bar=50 μ m, n=3.

Fig. 1 [Download full resolution image](#)

Fig. 2 [Download full resolution image](#)

Fig. 3 [Download full resolution image](#)

A

B

phycocyanin

C

Fibronectin Vimentin E-cadherin

D

Relative
expression level(%)

Fig. 4 [Download full resolution image](#)

Fig. 5 [Download full resolution image](#)

Fig. 6 [Download full resolution image](#)